All Comments by Stefan Lichtenthaler
- Too Basic: APP β-CTF's YENTPY Motif Binds Proton Pump, Thwarts Lysosomes
- Protective Alzheimer's disease-associated APP A673T variant predominantly decreases sAPPβ levels in cerebrospinal fluid and 2D/3D cell culture models.
- An isogenic panel of App knock-in mouse models: Profiling β-secretase inhibition and endosomal abnormalities.
- Vanquishing Brain Cancer: A New Mission for BACE inhibitors?
- New Knock-In Mice Rapidly Accumulate Amyloid Plaques
- Drop of Hope? No Cognitive Worsening on BACE Inhibitor
- New Data from Past BACE Inhibitor Trials Shed Light on Side Effects
- Paper Alert: Trafficking Variants Cause BACE Buildup in Axons
- Can BACE2 Protect Against Amyloidosis?
- End of the BACE Inhibitors? Elenbecestat Trials Halted Amid Safety Concerns
- Cognitive Decline Trips Up API Trials of BACE Inhibitor
- NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models.
- BACE and γ-Secretase Form Mega-Complex that Processes APP
- In Conditional BACE1 Knockouts, Hippocampal Axons Compromised
- Alzheimer’s Disease-Related Proteins Needed for Neurogenesis